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The interleukin-6 (IL-6) family of cytokines is a family of structurally and functionally related proteins, including IL-6, IL-11, leukemia inhibitory factor (LIF), oncostatin M (OSM), ciliary neurotrophic factor (CNTF), and cardiotrophin-1 (CT-1). These proteins
are also known as gp130 cytokines because they all share gp130 as a
common transducer protein within their functional receptor complexes. Several of these cytokines (LIF, OSM, CNTF, and CT-1) also
utilize the LIF receptor (LIFR) as a component of their receptor
complex. We have shown that all of these cytokines are capable of
activating both the JAK/STAT and p42/44 mitogen-activated protein kinase signaling pathways in 3T3-L1 adipocytes. By performing
a variety of preincubation studies and examining the ability of these
cytokines to activate STATs, ERKs, and induce transcription of
SOCS-3 mRNA, we have also examined the ability of gp130 cytokines to modulate the action of their family members. Our results
indicate that a subset of gp130 cytokines, in particular CT-1, LIF,
and OSM, has the ability to impair subsequent signaling activity
initiated by gp130 cytokines. However, IL-6 and CNTF do not
exhibit this cross-talk ability. Moreover, our results indicate that
the cross-talk among gp130 cytokines is mediated by the ability of
these cytokines to induce ligand-dependent degradation of the
LIFR, in a proteasome-independent manner, which coincides with
decreased levels of LIFR at the plasma membrane. In summary, our
results demonstrate that an inhibitory cross-talk among specific
gp130 cytokines in 3T3-L1 adipocytes occurs as a result of specific
degradation of LIFR via a lysosome-mediated pathway.

The interleukin 6 (IL-6)2 cytokine family is a group of functionally
and structurally related proteins including IL-6, IL-11, leukemia inhibitory factor (LIF), oncostatin M (OSM), ciliary neurotrophic factor
(CNTF), and cardiotrophin-1 (CT-1) (1, 2). All of these cytokines possess a similar helical structure and signal via structurally related receptor complexes. All of the IL-6 family cytokines were originally identified
as factors with distinct and unique properties (3– 8), yet it is currently
known that these cytokines can function in a pleiotropic and redundant
manner (9, 10). In fact, members of the IL-6 cytokine family play pivotal
roles in the immune, hematopoietic, nervous, cardiovascular, and endocrine systems, as well as in bone metabolism, inflammation, and acute
phase responses (11–21).
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All functional receptor complexes for the IL-6 cytokines use glycoprotein 130 (gp130) as a component required for both ligand binding
and signal transduction (15, 22–24). Hence, IL-6 family cytokines are
often referred to as gp130 cytokines. Several gp130 cytokines (LIF,
OSM, CNTF, and CT-1) also require the gp130-related protein LIFR
(LIF receptor) as a part of their functional receptor complexes (25–29).
In fact, these cytokines have very low affinity to gp130 until it becomes
a part of the LIFR/gp130 heterodimer. Apart from the shared functional
receptor components, IL-6, IL-11, OSM, and CNTF also have cytokinespecific receptor components, often referred to as the ␣-receptors
(30 –32).
Although LIF and CT-1 signal through a LIFR/gp130 heterodimer,
other gp130 cytokines have more distinct receptor complex structures.
IL-6 first binds to its ␣-receptor, IL-6R, and then two of these IL-6䡠IL-6R
complexes associate with gp130 each, allowing the formation of a gp130
homodimer (33, 34). A similar pattern has also been proposed for the
formation of IL-11 functional receptor complexes (31). OSM can either
signal through the LIFR/gp130 heterodimer (26, 35) or through its ␣-receptor OSMR associated with a gp130 subunit (36, 37). Structurally,
OSMR is closely related to both LIFR and gp130. However, neither
OSMR nor LIFR can bind OSM in the absence of gp130 subunit. The
␣-receptor for CNTF, CNTFR␣, is structurally closely related to extracellular region of IL-6R but is anchored to the cell membrane via a
glycosylphosphatidylinositol linkage. CNTF binds to CNTFR␣, followed by the recruitment of gp130 and LIFR by two of these dimers,
resulting in a hexameric receptor complex (38). The ␣-receptors for
IL-6, IL-11, and CNTF can also be found in a soluble form, and these
soluble receptors can bind their ligands in a manner identical to their
membrane-associated forms (39, 40). These soluble receptors have the
potential to confer cytokine responsiveness to cells expressing gp130
and LIFR that do not express membrane-associated forms of the ␣receptors (41, 42).
The ubiquitous expression of gp130 in every cell type examined
explains the pleiotropic nature of gp130 cytokine action, whereas shared
usage of gp130 by all these cytokines in part explains the redundancy of
their actions. Unlike gp130, LIFR and the specific ␣-receptors exhibit a
more tissue-specific expression (43) and therefore contribute to the
specificity of gp130 cytokine actions. Spatial and temporal expression of
the individual cytokines is another factor that contributes to the specificity of their actions (44).
Functionally, it is the formation of the gp130/gp130 homodimer or
the LIFR/gp130 heterodimer that is essential for the downstream signal
transduction of gp130 cytokines. The function of the ␣-receptor is to
recruit the ligand and aid in the formation of signal-transducing dimers
in response to the ligands that are themselves incapable of doing so.
After stimulation by gp130 cytokines, target cells undergo a wide variety
of fates: growth promotion, growth arrest, differentiation, or the expression of specific genes. The specificity of cytokine actions in a given cell
type arises not only from the differences in the receptor and cytokine
expression, but also from the differences in downstream signaling pathways activated by the cytokine.
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Upon stimulation by gp130 cytokines, the gp130 receptor itself
undergoes homo- or heterodimerization governed by the phosphorylated tyrosine residues on the cytoplasmic region of the protein. This
dimerization triggers the activation of cytoplasmic protein kinases associated with gp130 receptor. In the case of gp130, those kinases are JAK1,
JAK2, and TYK2 (45–50). Activated JAKs phosphorylate tyrosine residues in the distal part of gp130 and LIFR and provide docking sites for
Src homology 2 domain-containing proteins such as STATs. Even
though the STAT family consists of 7 members, it is generally recognized that gp130 cytokines activate STAT 3 and, to a lesser extent,
STAT 1 (51, 52). Once recruited to the receptor, STATs are phosphorylated and form dimers that translocate to the nucleus, bind DNA, and
modulate transcription. Stimulation by gp130 cytokines can also lead to
the activation of the p42/44 MAPK pathway (53).
Recent studies have shown that three different gp130 cytokines activate both the JAK/STAT and p42/44 MAPK signaling pathways in fat
cells (54 –57). Because these cytokines utilize many of the same signaling proteins, we examined the cross-talk among LIF, CT-1, OSM,
CNTF, and IL-6 in adipocytes. We also examined the ability of growth
hormone (GH), a potent STAT activator, to modulate gp130 cytokine
signaling. Our results demonstrate that a 2-h pretreatment with the
gp130 cytokines examined leads to the inhibition of their own subsequent signaling. Interestingly, LIF could also inhibit the signaling of
CT-1, CNTF, and OSM, but not IL-6. Similarly, CT-1 could inhibit its
own signaling or a cellular response to LIF and OSM. OSM also exhibited similar properties. Inhibition of signaling was measured by three
parameters: activation of STATs, activation of ERKs, and the induction
of SOCS-3 mRNA. Moreover, we observed that the cross-talk that
resulted in an inhibition of signaling correlated with the degradation of
the LIFR in a proteasome-independent manner and a loss of the LIFR at
the plasma membrane. In summary, our findings strongly suggest that
inhibitory cross-talk among specific gp130 cytokines in fat cells is mediated by the ligand-dependent lysosome-mediated degradation of the
LIFR.

EXPERIMENTAL PROCEDURES
Materials—Dulbecco’s modified Eagle’s medium was purchased
from Invitrogen. Bovine and fetal bovine sera were purchased from
Sigma and Invitrogen, respectively. Rat recombinant CNTF and human
recombinant CT-1 were purchased from Calbiochem. Recombinant
mouse IL-6 and recombinant human OSM were purchased from Bio
Source International. Mouse recombinant LIF was purchased from
Chemicon International. Insulin, human recombinant GH, leupeptin,
chloroquine, and cycloheximide were all purchased from Sigma.
Epoxomicin and MG132 were purchased from Boston Biochem. TRIzol
was purchased from Invitrogen. All STAT antibodies were monoclonal
IgGs purchased from Transduction Laboratories or polyclonal IgGs
purchased from Santa Cruz. The highly phospho-specific polyclonal
antibodies for STAT 1 (Tyr701), STAT 3 (Tyr705), and STAT 5 (Tyr694)
were IgGs purchased from BD Transduction Laboratories and Upstate
Biotechnology, Inc. LIFR and ERK1/ERK2 antibodies were rabbit polyclonal IgGs purchased from Santa Cruz. Active ERK antibody was a
rabbit polyclonal IgG purchased from Cell Signaling Technology.
Horseradish peroxidase-conjugated secondary antibodies were purchased from Jackson Immunoresearch. An Enhanced Chemiluminescence (ECL) kit was purchased from Pierce. Nitrocellulose and Zeta
Probe-GT membranes were purchased from Bio-Rad.
Preparation of Whole Cell Extracts—Monolayers of 3T3-L1 preadipocytes or adipocytes were rinsed with phosphate-buffered saline and
then harvested in a nondenaturing buffer containing 150 mM NaCl, 10
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mM Tris, pH 7.4, 1 mM EGTA, 1 mM EDTA, 1% Triton X-100, 0.5%
Nonidet P-40, 1 M phenylmethylsulfonyl fluoride, 1 M pepstatin, 50
trypsin inhibitory milliunits of aprotinin, 10 M leupeptin, and 2 mM
sodium vanadate. Samples were extracted for 30 min on ice and centrifuged at 15,000 rpm at 4 °C for 15 min. Supernatants containing whole
cell extracts were analyzed for protein content using a BCA kit (Pierce)
according to the manufacturer’s instructions.
Gel Electrophoresis and Western Blot Analysis—Proteins were separated in 5, 7.5, 10, or 12% polyacrylamide (acrylamide from National
Diagnostics) gels containing SDS according to Laemmli (58) and transferred to nitrocellulose membrane in 25 mM Tris, 192 mM glycine, and
20% methanol. After transfer, the membrane was blocked in 4% fat-free
milk for 1 h at room temperature. Results were visualized with horseradish peroxidase-conjugated secondary antibodies and ECL.
RNA Analysis—Total RNA was isolated from cell monolayers with
TRIzol according to the manufacturer’s instructions with minor modifications. For Northern blot analysis, 20 g of total RNA was denatured
in formamide and electrophoresed through a formaldehyde/agarose gel.
The RNA was transferred to Zeta Probe-GT, cross-linked, hybridized,
and washed as described previously (59). Probes were labeled by random priming using the Klenow fragment and [␣-32P]dATP.
Rodent Adipose Tissue Isolation—Animals were euthanized by cervical dislocation, and tissues were immediately removed and frozen in
liquid nitrogen. Frozen tissues were homogenized in a buffer containing
150 mM NaCl, 10 mM Tris, pH 7.4, 1 mM EGTA, 1 mM EDTA, 1% Triton
X-100, 0.5% Nonidet P-40, 1 M phenylmethylsulfonyl fluoride, 1 M
pepstatin, 50 trypsin inhibitory milliunits of aprotinin, and 10 M leupeptin, and 2 mM sodium vanadate. Homogenates were centrifuged for
10 min at 5,000 rpm to remove any debris and insoluble material and
then analyzed for protein content. All C57BL/6J mice were obtained
from a colony at the Pennington Biomedical Research Center. All animal studies were carried out with protocols that were reviewed and
approved by institutional IACUCs.
3T3-L1 Cell Membrane Fractionation—Untreated and LIF-treated
serum-deprived 3T3-L1 adipocytes were rinsed with buffer A (250 mM
sucrose, 20 mM HEPES, 1 mM EDTA, pH 7.4) at 37 °C and then harvested at 4 °C in buffer A and homogenized with a Teflon pestle. Total
membranes were pelleted at 250,000 ⫻ g for 90 min and resuspended in
buffer B (20 mM HEPES, 1 mM EDTA, pH 7.4). For some experiments,
membranes were fractionated into plasma membrane, intracellular
membranes (low density microsomes, LDM), and a nuclear/mitochondrial fraction as we have described previously (59). Membrane and cytosolic fractions were divided and immediately stored at ⫺70 °C. The
protein content for all fractions was determined with a BCA kit according to the manufacturer’s instructions.

RESULTS
One of the unifying features of all gp130 cytokines is their ability to
activate JAK/STAT and MAPK (ERK1/2) signaling pathways. We
therefore wanted to determine whether gp130 cytokines, which affect
these pathways in fat cells, can work synergistically to initiate these
signals, or whether their actions antagonize each other. To address this
question, we pretreated fully differentiated 3T3-L1 adipocytes with several different gp130 cytokines (IL-6, LIF, OSM, CNTF, and CT-1), as
well as with GH for 2 h. Next, we treated the cells for 15 min with either
CT-1, CNTF, LIF, or GH. As shown in Fig. 1, gp130 cytokines interacted
primarily in an antagonistic fashion. The results in Fig. 1A represent an
experiment in which 3T3-L1 adipocytes were pretreated with CT-1,
which is known to activate STAT 1 and 3 in these cells potently (60). We
observed that CT-1 signaling was impaired by a 2-h pretreatment with
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FIGURE 1. gp130 cytokine administration inhibits cell signaling of other gp130 cytokines. Fully differentiated 3T3-L1 adipocytes were preincubated with 2 ng/ml IL-6, 0.1 nM LIF,
0.5 ng/ml OSM, 125 ng/ml GH, 0.45 nM CNTF, or 0.2 nM CT-1 for 2 h. Next, the cells were treated for 15 min with CT-1 (A), CNTF (B), LIF (C), or GH (D). After the treatment, whole cell
extracts were prepared, and 150 g of each extract was separated by SDS-PAGE, transferred to nitrocellulose, and subjected to Western blot analysis. This is a representative
experiment performed independently two times.

several gp130 cytokines, including CT-1. Our results demonstrate that a
2-h pretreatment with LIF, OSM, or CT-1 completely blocked the
STAT 1 activation induced by a 15-min CT-1 treatment. These same
cytokines also interfered with the activation of STAT 3 by CT-1. In this
case, LIF acted as the most potent inhibitor, whereas CT-1 and OSM
pretreatments consistently resulted in a partial, but significant, inhibition of STAT activation. No substantial STAT 5 activation occurred
with CT-1 treatment, whereas GH pretreatment caused a robust STAT
5 activation that was detectable even after the 2-h pretreatment period.
The ability of LIF, OSM, and CT-1 to block further actions of CT-1 was
also evident through their effects on MAPK (ERK1/2) signaling because
the activation of this pathway by acute CT-1 was attenuated through
pretreatment with these cytokines.
Even though CNTF is not a potent activator of JAK/STAT or MAPK
signaling in adipocytes (54, 60), its ability to activate STAT 3 (first lane,
Fig. 1B) was affected by the pretreatment with all other gp130 cytokines
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examined, except for IL-6. As was the case with the acute CT-1 treatment, a 2-h pretreatment of adipocytes with LIF, OSM, or CT-1
decreased the magnitude of STAT 3 activation by CNTF. This pattern
of regulation was not observed with active MAPK, which we attribute to
the weak activation of this kinase by CNTF.
The data in Fig. 1C verify that LIF acts as a potent activator of JAK/
STAT and MAPK signaling in 3T3-L1 adipocytes. However, the ability
of LIF to activate STAT 1 and 5 was completely abolished by a 2-h
pretreatment with LIF, OSM, or CT-1. An identical pattern of inhibition
was also observed with the activation of MAPK (ERK1/2) by a 15-min
LIF treatment. Acute LIF administration resulted in a robust STAT 3
activation, and only the 2-h pretreatment with LIF resulted in an attenuation of STAT 3 activation. Hence, the gp130 cytokines LIF, OSM, and
CT-1 pretreatment inhibited the LIF-induced activation of STAT 1 and
5, but not of STAT 3.
Acute treatment with GH, shown in Fig. 1D, also leads to a robust

VOLUME 280 • NUMBER 40 • OCTOBER 7, 2005

gp130 Cytokine Cross-talk in Adipocytes

FIGURE 2. CT-1 treatment in vivo blocks subsequent CT-1 signaling in rodent fat pads. Sixweek-old male C57BL/6J mice were given an intraperitoneal injection of 0.05 nM CT-1 (0.25
g/animal) or vehicle (saline) control. Two animals
were used for each condition. After 4 (A) or 8 (B) h
the animals were injected again with CT-1 or vehicle. In this set of experiments, three animals were
used for each condition. 15 min after the second
injection the mice were sacrificed, and epididymal
fat pads were immediately removed and frozen in
liquid nitrogen. 150 g of each tissue extract was
separated by SDS-PAGE, transferred to nitrocellulose, and subjected to Western blot analysis. This is
a representative experiment performed independently two times.

induction of JAK/STAT and MAPK signaling, as evident by the activation of STAT 1, 3, and 5 and ERK1/2. However, unlike gp130 cytokines,
the ability of GH to activate these pathways was not affected by a 2-h
preincubation with any of the gp130 cytokines examined. In fact, LIF,
OSM, and CT-1 mildly enhanced the GH-induced activation of STAT
3, but not of STAT 1 and 5. The only inhibitory effect observed for GH
singling was the inhibition of STAT and MAPK activation after a 2-h
pretreatment with GH itself. STAT5A levels are shown in all panels of
Fig. 1 to demonstrate equivalent loading of whole cell extracts. The
expression of STAT 3 and total level of ERK1/2 (MAPK) also remained
unchanged by all of the treatments shown in Fig. 1 (data not shown).
We utilized a similar experimental approach in an in vivo model to
examine further the nature of interactions among gp130 cytokines.
C57BL/6J mice were injected with either 0.05 nM CT-1 or the appropriate vehicle (saline) control, then injected again either four (Fig. 2A) or
eight (Fig. 2B) h later, and then sacrificed 15 min after the second round
of injections. As shown in Fig. 2, acute intraperitoneal administration of
CT-1 lead to the activation of STAT 3 in mouse epididymal fat pads.
Interestingly, MAPK (ERK1/2) was active even in animals injected with
vehicle (saline) control. As expected, phosphorylated STAT 3 proteins
were present in the adipose tissue extracts from mice after a 15-min
injection with CT-1. We still observed active STAT 3 at 4 h after CT-1
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administration (Fig. 2A) at levels comparable with that following a
15-min treatment. In an independent experiment, six animals were pretreated with CT-1 after an intraperitoneal injection with CT-1 or vehicle, and epididymal fat pads were harvested for analysis. We observed
that the active forms of both STAT 3 and MAPK were absent from the
fat pads 8 h after a CT-1 injection (Fig. 2B). The animals injected with
CT-1 for 4 h, and then again for 15 min (Fig. 2A), showed no additional
increase in STAT 3 or MAPK activation compared with animals
injected with CT-1 for 15 min or 4 h only. Yet, in the fat pads of mice
injected with CT-1 for 8 h, and then again for 15 min (Fig. 2B), we
observed no increase in STAT 3 or MAPK activation compared with
animals injected with CT-1 for 8 h only. Total MAPK levels are shown to
demonstrate equivalent levels of protein loading. In summary, these
results clearly demonstrate that pretreatment of mice with CT-1 blocks
the acute STAT 3 activation by CT-1 in adipose tissue.
We have shown previously that the activation of the JAK/STAT pathway in 3T3-L1 adipocytes by gp130 cytokines is associated with the
induction of SOCS-3 mRNA (60). Therefore, we also examined the
effects of gp130 cytokine interaction on the induction of SOCS-3
mRNA. As shown in Fig. 3A, the ability of a 40-min LIF treatment to
induce SOCS-3 mRNA expression was impaired by a 2-h pretreatment
with LIF, CT-1, and, to a lesser degree, by OSM. Conversely, IL-6,
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FIGURE 3. Cross-talk among gp130 cytokines inhibits the induction of SOCS-3
mRNA. Fully differentiated 3T3-L1 adipocytes were preincubated with 2 ng/ml IL-6, 0.1
nM LIF, 0.5 ng/ml OSM, 125 ng/ml GH, 0.45 nM CNTF, or 0.2 nM CT-1 for 2 h. The cells were
then treated for 45 min with either LIF (A) LIF or GH (B). After the treatment total RNA was
collected from the cells, and 20 g of each total RNA was electrophoresed, transferred to
nylon, and subjected to Northern blot analysis. This is a representative experiment performed independently three times.

CNTF, or GH pretreatment had no effect on the LIF-induced increase
of SOCS-3 mRNA. Pretreatments with LIF, OSM, or CT-1, but not IL-6,
CNTF, or GH, also attenuated the induction of SCOS-3 mRNA by OSM
and CT-1 (data not shown). Consistent with the data shown in Fig. 1D,
pretreatment with gp130 cytokines did not inhibit the ability of GH to
induce SOCS-3 mRNA. In fact, LIF, OSM, and CT-1 seemingly
enhanced the GH-induced increase in SOCS-3 mRNA expression,
much like their synergistic effect on STAT 3 activation observed in Fig.
1D. In addition, the data shown in Fig. 3B clearly indicate that the
increase in SOCS-3 mRNA expression induced by GH was only inhibited by pretreatment with GH, but not by any of the gp130 cytokines
examined. In these figures, 18 and 28 S ribosomal RNAs are shown to
demonstrate even loading of total RNA.
Another common feature of gp130 cytokines is their shared use of
gp130 and LIFR proteins as signal transducers that comprise their
receptor complexes. Therefore, we examined the effect of gp130 cytokine signaling on the expression and decay of these two receptor components. As shown in Fig. 4A, the expression levels of LIFR in fully
differentiated 3T3-L1 adipocytes dramatically decreased within 6 h in
the absence of de novo protein synthesis (achieved through incubation
with cycloheximide). Addition of LIF, a ligand for LIFR, further accelerated this degradation process. In the presence of ligand, we observed a
significant decrease in LIFR levels within 1 h of the treatment, and no
protein was detectable after 4 h. Addition of a proteasome inhibitor,
MG132, failed substantially to prevent the loss of LIFR protein under
basal conditions. Moreover, this inhibitor did not have a marked effect
on the increased decay of LIFR after LIF treatment. However, the addition of lysosome inhibitors leupeptin and chloroquine prevented the
degradation of LIFR under both basal and LIF-treated conditions. These
findings were confirmed by the experiment shown in Fig. 4B. In this
case, we used a highly specific proteasome inhibitor, epoxomicin, in lieu
of MG132. The data shown clearly indicate that the loss of LIFR after a
6-h treatment with cycloheximide was not affected by epoxomicin but
was prevented with a combination of leupeptin and chloroquine. Furthermore, the addition of LIF alone, or in the presence of epoxomicin,
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FIGURE 4. Administration of LIF alters the half-life of LIFR protein in adipocytes. A,
fully differentiated 3T3-L1 adipocytes were treated with 0.1 nM LIF, 20 M MG132, a
mixture of 200 M chloroquine and 10 M leupeptin (L/C), or a combination of LIF and the
inhibitors. The treatments were done in the presence of 5 M cycloheximide (CH). Whole
cell extracts were prepared from untreated (0) or adipocytes treated at the times indicated. B, whole cell extracts were prepared from fully differentiated 3T3-L1 adipocytes
that were untreated (CTL) or treated for 6 h with 0.1 nM LIF, 100 nM epoxomicin (EPX), a
mixture of 200 M chloroquine and 10 M leupeptin, or a combination of LIF and the
inhibitors, in the presence of 5 M cycloheximide. In each panel, 150 g of extract was
separated by SDS-PAGE, transferred to nitrocellulose, and subjected to Western blot
(WB) analysis. This is a representative experiment performed independently two times.

FIGURE 5. Half-life of LIFR protein in adipocytes is decreased by gp130 cytokine
administration in a proteasome-independent manner. Whole cell extracts were prepared from 3T3-L1 adipocytes treated with 0.1 nM LIF, 0.2 nM CT-1, 0.45 nM CNTF, 0.5
ng/ml OSM, 2 ng/ml IL-6, or 125 ng/ml GH for 4 h in the presence of 5 M cycloheximide
(CH), or a mixture of 5 M cycloheximide and 200 M chloroquine and 10 M leupeptin
(L/C). 100 g of each sample was separated by SDS-PAGE, transferred to nitrocellulose,
and subjected to Western blot analysis. This is a representative experiment performed
independently three times.

resulted in a complete loss of LIFR protein, whereas the combination of
leupeptin and chloroquine completely prevented this loss. Consistent
with previously reported findings (61, 62), the levels of gp130 protein
remained unchanged throughout all of the treatments (data not shown
and see Fig. 7). Total MAPK (ERK1/2) levels are also shown to demonstrate even loading of protein samples.
To elucidate why LIF, CT-1, and OSM seemed to have prominent
inhibitory effects on gp130 cytokine signaling, we examined the ability
of all gp130 cytokines to affect the expression levels of LIFR protein in
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FIGURE 6. Cross-talk among gp130 cytokines is abolished by inhibiting LIFR degradation in a lysosome-dependent manner. Fully differentiated 3T3-L1 adipocytes were
preincubated with 0.2 nM CT-1 , 0.1 nM LIF, 0.5 ng/ml OSM, or 125 ng/ml GH for 2 h in the
presence of 200 M chloroquine and 10 M leupeptin (L/C). The cells were then treated
for 15 min with CT-1. After the treatment, whole cell extracts were prepared, and 150 g
of each extract was separated by SDS-PAGE, transferred to nitrocellulose, and subjected
to Western blot analysis. This is a representative experiment performed independently
three times.

3T3-L1 adipocytes. As shown in Fig. 5, a 4-h incubation with cycloheximide induced a notable decrease in LIFR levels. However, addition of
LIF, CT-1, or OSM to these cells resulted in a complete or, in the case of
OSM, a nearly complete loss of LIFR expression. Interestingly enough,
the addition of CNTF, IL-6, or GH did not induce a decrease in LIFR
levels greater than the decrease induced by cycloheximide. Consistent
with the data from Fig. 4, the loss of LIFR expression through the action
of cycloheximide alone, or with LIF, CT-1, and OSM, was blocked by the
addition of leupeptin and chloroquine to the cell media. Total MAPK
(ERK1/2) levels are shown as controls for even loading.
Because the inhibitory effects of LIF, CT-1, and OSM correlated with
their ability to induce a decrease in LIFR protein levels, and the loss of
LIFR could be reversed by leupeptin and chloroquine, we tested whether
the addition of leupeptin and chloroquine could reverse the inhibitory
effects of LIF, CT-1, and OSM on JAK/STAT and MAPK signaling.
Consistent with Fig. 1A, the data in Fig. 6 demonstrate that CT-1, LIF, or
OSM administration significantly impairs the ability of CT-1 to activate
STATs 1 and 3, as well as MAPK (ERK1/2) in adipocytes. Once again,
GH demonstrated no such ability. However, the addition of leupeptin
and chloroquine to adipocytes prior to cytokine administration reversed
the inhibitory effects of CT-1, LIF, and OSM, as evidenced by the ability
of CT-1 to activate STATs 1 and 3, and MAPK (ERK1/2) in these cells.
Total MAPK (ERK1/2) levels are shown as even loading controls in this
experiment.
To determine whether the inhibition of LIF signaling was mediated
by a decrease in the levels of LIFR on the cell surface, we isolated membrane fractions from LIF-treated cells that had been previously
untreated or pretreated with LIF. As shown in Fig. 7A, an examination of
whole extracts confirmed that a 2-h LIF pretreatment resulted in a
decrease of LIFR expression and the ability of LIF to induce signaling,
evident by the activation of MAPK (ERK1/2) in the cells. However, we
did not observe any decrease in gp130 levels. These whole cell extracts
were also used for membrane fractionation to isolate plasma membrane
and LDM fractions. After an acute LIF stimulation (Fig. 7B), high levels
of LIFR were still present at the plasma membrane. Yet, we observed a
decrease in LIFR at the plasma membrane in cells pretreated with LIF,
without significant change in the levels of LIFR in LDM. There was no
change in the levels of gp130 in either membrane compartment with
any of the treatment conditions.
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FIGURE 7. LIF pretreatment results in deceased levels of LIFR on the plasma membrane. Fully differentiated 3T3-L1 adipocytes were preincubated with 0.1 nM LIF for 2.5 h,
followed by a 15-min LIF treatment. The whole cell extracts (WCE) (A) and the plasma
membrane (PM) and low density microsome fractions (LDM) (B) were isolated from the
treated cells. An equal amount of each type of extract (100 g of WCE, 40 g of PM, and
20 g of LDM) was separated by SDS-PAGE, transferred to nitrocellulose, and subjected
to Western blot analysis. This is a representative experiment performed independently
two times.

DISCUSSION
Synchronous functional redundancy and specificity may be the most
interesting characteristic of gp130 cytokine biology (10, 11). Although
the specific mechanisms governing the actions of these cytokines are
still unknown, there is a general consensus regarding several aspects of
gp130 cytokine signaling. Foremost, all members of the gp130 cytokine
family use gp130 protein as a trans-membrane signal transducer within
their functional receptor complexes (22, 24). Also, gp130 is crucial for
the recruitment of other receptor complex components (63) and for the
propagation of signal to the downstream targets, such as the components of the JAK/STAT or MAPK pathways (47, 50). Several gp130
cytokines (LIF, OSM, CNTF, CT-1) use LIFR as a part of their functional
receptor complexes (25–29). Both gp130 and LIFR are expressed in vivo
as well as in cultured adipocytes (54, 64), and many studies have shown
that various gp130 cytokines have the ability to induce intracellular
signaling in these cell types (54, 60, 65, 66).
In our studies, we examined whether gp130 cytokines can act synergistically to activate their downstream targets or whether their actions
antagonize the ability of the individual cytokine to induce signaling. The
results from our studies support the latter scenario. CT-1, LIF, and
OSM could attenuate or, in some cases, completely abolish, subsequent
signaling by their family members. CNTF or IL-6 did not have the same
capabilities. There was no the inhibitory cross-talk between gp130 cytokines and GH. GH was only able to interfere with its own signaling. In
fact, our data in Figs. 1 and 3 suggest that CT-1, LIF, and OSM may have
synergistic effects on GH-induced STAT 3 activation and the induction
of SOCS-3 mRNA. These results suggest that the attenuation of gp130
cytokine signaling does not occur primarily at the level of intracellular
signal transducers. If this were the case, then GH signaling would have
been affected as well because it propagates its signal through the JAK/
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STAT and MAPK pathways, in a manner similar to gp130 cytokines
(67). Rather, it is indicative of a signaling inhibition at the receptor level
because GH does not share receptor components with the members of
gp130 cytokine family. Our observations that LIFR is decreased at the
plasma membrane support these observations (Fig. 7).
Interestingly, the results from our in vivo study were also consistent
with our findings. Unlike in 3T3-L1 adipocytes, STAT 3 and MAPK
activation by CT-1 was sustained throughout a 4-h pretreatment period
in live animals. However, no additional STAT 3 or MAPK activation
occurred after a subsequent 15-min CT-1 treatment, demonstrating the
inhibitory effect of the pretreatment. The inhibitory effect of CT-1 pretreatment was particularly evident after an 8-h pretreatment period.
This extended time frame allowed the activated STAT 3 and MAPK
levels to return to basal. Because of the limited scope of our study, we
have not yet examined whether the inhibitory cross-talk in vivo occurs,
but, based on our in vitro results, we predict that LIF and OSM pretreatment would also attenuate CT-1 signaling in vivo.
We also demonstrated that the ability of gp130 cytokines to inhibit
the initiation of signaling by their family members results in marked
changes in target gene expression. In these studies, we observed a loss in
the induction in SOCS-3 mRNA coincided with an impairment of signaling by gp130 cytokines. Similar findings were recently reported by a
group studying OSM-mediated induction of SOCS-3 mRNA in cultured human umbilical vein endothelial cells (68). The results of our
experiment are very important because they clearly demonstrate that
the inhibition of signal induction is also observed in the nucleus at the
level of gene transcription. Furthermore, our results suggest that there
are no compensatory mechanisms by which the cells can maintain a
particular level of signaling by some cytokines when faced with reduction in signaling because of the inhibitory cross-talk of gp130 cytokines.
Because our experiments suggested a possible inhibition of signaling
at the level of the receptor, we examined the effects of gp130 cytokines
on the expression and stability of LIFR. Previous studies have shown
that gp130 cytokine signaling affects the turnover and degradation of
LIFR while having no effect on gp130 (61, 62). Consistent with these
findings, we have shown that the half-life of LIFR is dramatically shortened by LIF administration in 3T3-L1 adipocytes. We have also demonstrated that basal or ligand-induced degradation of LIFR can be prevented by the addition of lysosomal inhibitors. However, proteasome
inhibitors did not alter the half-life of LIFR under basal conditions or
after LIF administration. In addition to LIF, both CT-1 and OSM had
profound effects on LIFR degradation. All of these cytokines use LIFR as
a component of their receptor complexes and therefore induce its endocytosis and degradation (62). The effect of CNTF was marginal, whereas
IL-6 and GH had no effect on LIFR levels. IL-6 signals via the complex of
gp130 and IL-6R␣ and therefore does not affect LIFR, whereas the
receptor for GH shares no common components with gp130 cytokine
receptor complexes. CNTF signals through the receptor complex of
gp130, LIFR, and CNTFR␣. However, differentiated 3T3-L1 adipocytes
do not express CNTFR␣ (54), so the ability of this cytokine to form
functional receptor complexes, and therefore induce LIFR degradation,
is severely impaired. Consistent with our previous experiment, inhibition of the lysosome with leupeptin and chloroquine completely prevented the loss of LIFR following gp130 cytokine treatment.
However, one of our most interesting findings was the fact that the
inhibition of the lysosome prior to cytokine administration completely
blocks the ability of gp130 cytokines to impair signaling of their family
members. Together with the subcellular fractionation data, these results
strongly suggest that the loss of LIFR protein during the pretreatment
period prevents the initiation of subsequent signaling events by cytokine
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administration and that the inhibitory cross-talk is not the result of a
direct effect on STATs, but rather the decreased levels of LIFR on the
plasma membrane.
In summary, a striking parallel has emerged during this study, linking
the ability of a specific gp130 cytokine to block its own signaling or the
signaling of other gp130 cytokines in a manner that correlates with the
degradation of LIFR. Specifically, CT-1, LIF, and OSM, the cytokines
with the strongest inhibitory effects on the signaling of their family
members, were also the most potent inducers of lysosome-mediated
LIFR degradation. We hypothesized that their ability to inhibit, or at
least attenuate, the signaling of gp130 cytokines is associated with their
ability to induce LIFR degradation and limit the availability of LIFR for
the formation of receptor complexes required for further stimulation of
signaling by gp130 cytokines. Conversely, CNTF, IL-6, and GH did not
affect the turnover of the LIFR and therefore did not inhibit the signaling abilities of other gp130 cytokines. Further studies will be necessary
to elucidate the exact fate of LIFR after cytokine treatment and to determine whether lysosomal inhibition prevents endocytosis of LIFR, as well
as its degradation. However, our data clearly demonstrate that lysosomal inhibitors reverse the ability of CT-1, LIF, and OSM pretreatment
to inhibit gp130 cytokine-induced STAT activation, suggesting that the
cross-talk among these cytokines occurs because of LIFR endocytosis,
which makes this protein unavailable for further signaling events. These
findings provide a strong basis for future studies on cytokine interactions that could be used to mimic various disease states marked by
simultaneous expression of several cytokines, or to create novel
approaches in inducing the differentiation of various progenitor cell
lines (69, 70). This system may also be used to understand the signaling
events in adipocytes under the influence of macrophages. Two recent
studies (55, 71) have demonstrated that macrophage accumulation in
adipose tissue, and subsequent secretion of cytokines by these macrophages, could possibly be some of the initial events leading to the onset
of obesity and type 2 diabetes.
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